V. Kolek (Olomouc, Czech Republic), T. Bauer (Bochum, Germany)
Diagnosis of pulmonary infection with bacteriological and pathological examinations of lung necropsy material
G. Bozkirlioglu, N. Batar, G. Apaydin Salar, S. Aydemir, D. Nart, A. Atasever, A. Guzelant, F. Bacakoglu, M. A. Ozinel, A. Veral (Izmir, Turkey)
|  |
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives
T. T. Bauer, T. Pfeil, C. Ernen, D. Daniel, B. M. Schlosser, I. M. Thate-Waschke, R. Rychlik (Bochum, Burscheid, Leverkusen, Germany)
| |
Automated analysis of squawks
R. Murphy, A. Vyshedskiy, R. Paciej (Boston, United States Of America)
| |
Endothelial cell compatibility of azithromycin and erythromycin
C. Armbruster, B. Robibaro, A. Griesmacher, M. M. Müller (Vienna, Austria)
| |
Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002
D. J. Farrell, J. Pluim, R. B. Nieman (London, United Kingdom; Bridgewater, United States Of America)
| |
Efficacy of the neuraminidase inhibitors in treating influenza pneumonia
N. Takayanagi, T. Kato, D. Tokunaga, H. Matsushima, M. Ubukata, K. Kurashima, T. Yanagisawa, Y. Sugita (Saitama, Japan)
| |
Fatal outcome in lower respiratory tract infections
G. P. Trakada, E. N. Prodromaki, D. Dougenis, P. Goumas, K. V. Spiropoulos (Patras, Greece)
| |
Defining community-acquired pneumonia severity on presentation to hospital: a derivation study
F. J. Saldias, A. R. Diaz, G. Farias, L. Villarroel, G. Valdivia (Santiago, Chile)
| |
In-hospital mortality for community acquired pneumonia and evaluation according to national diagnosis and treatment guidelines
N. Kiral, A. Fidan, I. Erdem, A. Eren, B. Çaglayan (Istanbul, Turkey)
| |
Diagnostic value of procalcitonin in lower respiratory tract infection
D. Jaccard-Stolz, C. C. Mirjam, M. M. Gencay, B. Roland, P. Huber, B. Müller, M. Tamm (Basel, Switzerland)
| |
Are severity scores for community acquired pneumonia being used in secondary care and its impact on appropriateness of antibiotic therapy - a retrospective study
D. Park, H. Moudgil, T. Tjiu, K. S. Srinivasan (Telford, United Kingdom)
| |
Rational antimicrobial therapy of slowly resolving or nonresolving pneumonia
D. V. Petrova, Y. N. Shoikhet, P. B. Tatarincev (Barnaul, Russia)
| |
Comparison of the results of gram stain and non-specific cultures in sputum collected from patients with lower respiratory tract infections
N. T. Hoca, A. S. Yurdakul, F. Cimen, M. Atasever, A. Cakaloglu, T. Sipit, S. Atikcan (Ankara, Turkey)
| |
Meta analysis of hospitalized patients with community-acquired pneumonia (CAP) treated with levofloxacin
G. Hoeffken, K. Roscher (Dresden, Bad Soden, Germany)
| |
Faster clinical improvement and earlier discharge from hospital in CAP patients under sequential moxifloxacin treatment compared to standard therapy
T. Welte (Magdeburg, Germany)
| |
Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients
F. J. Saldias, A. R. Diaz, C. Torres, L. J. Flores, J. M. Mardonez (Santiago, Chile)
| |
Evaluation of macrolide resistance of streptococcus pneumoniae in southern Brazil
F. Rowe, C. A. G. Dias, E. W. Zettler, C. C. Fritscher (Porto Alegre, Brazil)
| |
CAP 2002 retrospective analysis prior to implementation of Italian internal medicine guidelines: preliminary results
F. Blasi, A. Bulfoni, R. Cosentini, S. Costantino, G. Fabio, I. Iori, D. Legnani, G. Lo Pinto (Milan, Udine, Rome, Reggio Emilia, Ligure, Italy)
| |
Difference of immune response in patients with severe acute pneumonia and lung abscesses
L. A. Kolodkina, N. A. Shcljarevitch, S. V. Orlov, T. P. Ses (St Petersburg, Russia)
| |